RSS Feeds
Drugs Five Years Later: Bleomycin
Abstract
Bleomycin was approved by the Food and Drug Administration in 1975 for therapy against squamous cell carcinomas, testicular cancers, and malignant lymphomas. An extensive bibliography on this drug indicates that there is little evidence of activity against other malignancies. Although initially used exclusively as a single agent, bleomycin has been considered recently for use in combination chemotherapy. Because of associated toxicity involving the lung and mucous membranes, bleomycin should be used cautiously by physicians, particularly in noninvestigational settings.
Article and Author Information
-
▸From the University of Rochester Cancer Center and the Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester; and Bristol Laboratories and the Departments of Pharmacology and Medicine, State University of New York-Upstate Medical Center, Syracuse; New York.
-
▸Requests for reprints should be addressed to John M. Bennett, M.D.; University of Rochester Cancer Center, Box 704, 601 Elmwood Avenue; Rochester, NY 14642.
-
- Received October 4, 1978.
- Accepted February 15, 1979.
- © 1979 American College of Physicians
